There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adicet Bio (ACET – Research Report), Masimo (MASI – Research Report) and Acumen Pharmaceuticals (ABOS – Research Report) with bullish sentiments.
Adicet Bio (ACET)
In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Adicet Bio, with a price target of $20.00. The company’s shares closed last Monday at $4.66, close to its 52-week low of $4.18.
According to TipRanks.com, Zelin is a 4-star analyst with an average return of
Adicet Bio has an analyst consensus of Moderate Buy, with a price target consensus of $24.33, representing a 422.1% upside. In a report issued on June 13, JonesTrading also maintained a Buy rating on the stock with a $25.00 price target.
See today’s best-performing stocks on TipRanks >>
Masimo (MASI)
In a report released today, Marie Thibault from BTIG assigned a Buy rating to Masimo, with a price target of $200.00. The company’s shares closed last Monday at $162.76.
According to TipRanks.com, Thibault is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Masimo with a $190.50 average price target.
Acumen Pharmaceuticals (ABOS)
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Acumen Pharmaceuticals, with a price target of $22.00. The company’s shares closed last Monday at $4.85.
According to TipRanks.com, Shrader is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acumen Pharmaceuticals with a $15.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
